An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

NCT05277987 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

CAR T-Cell Therapy

Interventions

DRUG: HEC-016(0.5×10^6 CAR-T Cells)
DRUG: HEC-016(0.5×10^6.5 CAR-T Cells)
DRUG: HEC-016(0.5×10^7 CAR-T Cells)

Sponsor

Shenzhen Fifth People's Hospital